Pfizer Inc. (PFE)
Are Investors Undervaluing Pfizer (PFE) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Curious about Pfizer (PFE) Q1 Performance? Explore Wall Street Estimates for Key Metrics
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Pfizer (PFE), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2025.
Pfizer Stock Before Q1 Earnings Release: To Buy or Not to Buy?
PFE's non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in the first quarter.
Analysts Estimate Pfizer (PFE) to Report a Decline in Earnings: What to Look Out for
Pfizer (PFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Pfizer Inc. (NYSE: PFE) Price Prediction and Forecast 2025-2030 (April 2025)
Shares of Pfizer ( NYSE: PFE ) have been battered over the past month, falling by -16.44%, outpacing the market's loss of -9.44% over the same period.
Pfizer: Is The Dividend Yield Worth The Effort
Despite its historical underperformance and declining dividend growth trajectory, Pfizer's 7.63% dividend yield is attractive, making it a compelling income stock candidate. CEO Bourla's strategic focus on R&D, cost-cutting, and new revenue streams from acquisitions aims to mitigate upcoming revenue losses and drive future growth. Despite current challenges, Pfizer's robust cash flow, cost-saving initiatives, and potential new blockbusters by 2030 present a speculative but promising investment opportunity.
Pfizer Abandons Its Leading Weight Loss Candidate. Should You Sell the Stock?
Although it isn't the largest therapeutic area in the pharmaceutical industry, the market for weight loss therapies has caught fire in recent years. The leading medicines in this field include household names such as Wegovy and Zepbound, two drugs whose sales are rapidly growing.
Pfizer (PFE) Laps the Stock Market: Here's Why
Pfizer (PFE) closed the most recent trading day at $22.15, moving +0.48% from the previous trading session.
Pfizer: Risks Priced In, Buy The Exceptional Valuation And Yield
Pfizer has faced headwinds post-COVID, but remains a key player with a robust R&D pipeline and an attractive 7.5%+ dividend yield. The pharmaceutical industry thrives on high R&D investment and patent protections, making Pfizer's development pipeline crucial for long-term growth. Despite recent setbacks, Pfizer's strategic initiatives, including cost-cutting and acquisitions, position it for future profitability and market leadership.
Pfizer: Tasty 7% Yield
Pfizer Inc.'s stock is trading at $22 with an 8% dividend yield, driven by market fears over losing vaccine revenues. The biopharma has a robust pipeline with potential mega blockbuster cancer drugs and a reduced reliance on Covid-related sales. The company maintains robust cash flows, covering R&D and dividends, and recently sold $6 billion in Haleon shares, boosting liquidity.
Viking Therapeutics' VK2735 Candidate Likely Boosted By Pfizer's Woes
13-week data from the Viking Therapeutics, Inc. phase 2 VENTURE-Oral Dosing trial using oral VK2735 for the treatment of patients with obesity, expected 2nd half of 2025. Pfizer's recent setbacks in weight-loss drugs may prompt it to consider acquiring VKTX, adding VK2735 and VK2809 to its pipeline. VK2735's dual administration routes and dual GLP-1/GIP agonist mechanism position it as a strong contender in the growing $37.94 billion anti-obesity market.
